Despite the low number of patients with SCLC, significant results for therapy monitoring were also found for CEA and NSE prior to cycles 2 and 3, which certainly would have to be confirmed in larger patient cohorts. The gene discussed is CEACAM5; the disease is small cell lung carcinoma.